Phase 2a Trial Evaluating the Safety of Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Nanology
- 07 Nov 2017 According to a NanOlogy media release, the first patient has been enrolled in this trial.
- 04 Oct 2017 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 Planned initiation date changed from 15 Aug 2017 to 1 Sep 2017.